Browse Locations ... - Condition: Herpes Simplex Virus
Intervention: Device: Genexpert assay
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham
Not yet recruiting - verified June 2013 - Conditions: Cannabis Dependence; Anxiety Disorders
Interventions: Behavioral: Cognitive-Behavioral Therapy; Behavioral: Motivation Enhancement Therapy; Behavioral: Integrated Cannabis and Anxiety Reduction Treatment; Behavioral: False Safety Behavior Elimination Therapy
Sponsors: Louisiana State University and A&M College; Louisiana State University and A&M College; National Institute on Drug Abuse (NIDA)
Recruiting - verified June 2013 - Condition: Trichomonas Vaginalis
Intervention:
Sponsors: Tulane University Health Sciences Center; Tulane University Health Sciences Center; Louisiana State University Health Sciences Center in New Orleans
Recruiting - verified June 2013 - Condition: Overactive Bladder
Interventions: Drug: dexmecamylamine; Drug: Placebo
Sponsors: Targacept Inc.; Targacept Inc.
Recruiting - verified June 2013 - Condition: Type 2 Diabetes
Intervention: Other: NM504
Sponsors: NuMe Health; NuMe Health; Pennington Biomedical Research Center
Recruiting - verified May 2013 - Conditions: Opioid Dependence; Acute Opioid Withdrawal Syndrome
Interventions: Drug: Lofexidine HCl; Drug: Lofexidine-matching sugar pill
Sponsors: US WorldMeds LLC; US WorldMeds LLC; National Institute on Drug Abuse (NIDA)
Recruiting - verified June 2013 - Condition: Atopic Dermatitis
Interventions: Drug: Dupilumab (REGN668/ SAR231893); Drug: Placebo
Sponsors: Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Sanofi
Recruiting - verified May 2013 - Condition: Prediabetic Hyperglycemia
Interventions: Drug: Sitagliptin-Metformin; Drug: Metformin extended release (XR); Drug: Placebo pill
Sponsors: BC Women's Hospital & Health Centre; BC Women's Hospital & Health Centre; Merck
Not yet recruiting - verified June 2013 - Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: GFF MDI; Drug: GP MDI; Drug: FF MDI; Drug: Open-label tiotropium bromide inhalation powder; Drug: Placebo MDI
Sponsors: Pearl Therapeutics, Inc.; Pearl Therapeutics, Inc.
Recruiting - verified June 2013 - Condition: Congestive Heart Failure
Interventions: Drug: D-ribose; Other: Placebo
Sponsors: RiboCor, Inc.; RiboCor, Inc.
Not yet recruiting - verified May 2013 - Condition: Chronic Hepatitis C Virus
Interventions: Drug: Sofosbuvir/Ledipasvir 400/90 mg; Drug: Ribavirin
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013 - Condition: Vulvovaginal Atrophy
Interventions: Drug: Estradiol Vaginal Gel; Drug: Vehicle
Sponsors: Warner Chilcott; Warner Chilcott
Recruiting - verified June 2013 - Condition: Multiple Myeloma
Intervention:
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AbbVie
Recruiting - verified June 2013 - Condition: Diabetic Foot Ulcer
Interventions: Device: Oasis; Other: Standard
Sponsors: Healthpoint; Healthpoint
Recruiting - verified June 2013 - Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: QVA149; Drug: fluticasone/salmeterol
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified June 2013 - Condition: Relapsed or Refractory Mantle Cell Lymphoma
Intervention: Drug: Ibrutinib
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.; Pharmacyclics
Recruiting - verified June 2013 - Conditions: Vaginitis Trichomonal or Due to Trichomonas; Partner Communication
Interventions: Drug: Metronidazole 250 mg BID; Drug: PDPT; Drug: Single dose; Other: PR
Sponsors: Tulane University Health Sciences Center; Tulane University Health Sciences Center
Recruiting - verified June 2013 - Condition: Meningococcal Vaccine
Interventions: Biological: rLP2086; Biological: rLP2086; Biological: rLP2086; Biological: Havrix (HAV); Biological: Saline
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013 - Conditions: Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer
Interventions: Drug: oxaliplatin; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: 5-fluorouracil; Drug: capecitabine; Radiation: radiation; Procedure: surgery; Drug: gemcitabine hydrochloride
Sponsors: Alliance for Clinical Oncology Trials; Alliance for Clinical Oncology Trials; National Cancer Institute (NCI)
Recruiting - verified April 2013 - Condition: Schizophrenia
Interventions: Drug: Lurasidone; Drug: Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2; Drug: Placebo
Sponsors: Sunovion; Sunovion
Recruiting - verified June 2013 - Conditions: Atrial Fibrillation; Percutaneous Coronary Intervention
Interventions: Drug: rivaroxaban 2.5 mg; Drug: rivaroxaban 15 mg; Drug: rivaroxaban 10 mg; Drug: aspirin (ASA); Drug: vitamin K antagonist (VKA); Drug: clopidogrel; Drug: prasugrel; Drug: ticagrelor
Sponsors: Janssen Scientific Affairs, LLC; Janssen Scientific Affairs, LLC; Bayer Pharma AG
Recruiting - verified May 2013 - Condition: Hypogonadism
Interventions: Drug: Testosterone Solution; Drug: Placebo Solution
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013 - GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular UltrasoundCondition: Hypercholesterolemia
Interventions: Drug: AMG 145; Other: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified June 2013 - Condition: Chronic Hepatitis C Infection
Interventions: Drug: ABT-450/r/ABT-267; Drug: ABT-333; Drug: Ribavirin; Drug: Placebo for Ribavirin
Sponsors: AbbVie; AbbVie
Recruiting - verified May 2013 - Condition: Peripheral Arterial Disease
Interventions: Drug: edoxaban; Drug: Clopidogrel; Drug: Aspirin
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.; UMC Utrecht
Recruiting - verified June 2013 - Conditions: Type 2 Diabetes; Comparative Effectiveness of Glycemia-lowering Medications
Interventions: Drug: Sulfonylurea (glimepiride); Drug: DPP-4 inhibitor (sitagliptin); Drug: GLP-1 receptor agonist (liraglutide); Drug: Insulin (glargine)
Sponsors: GRADE Study Group; GRADE Study Group; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Becton, Dickinson and Company; Bristol-Myers Squibb; Merck; Novo Nordisk; Hoffmann-La Roche; Sanofi
Recruiting - verified May 2013 - Condition: Low Back Pain
Interventions: Drug: Hydrocodone bitartrate extended-release tablets; Drug: Matching placebo
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified May 2013 - Condition: Hyperparathyroidism, Secondary
Interventions: Drug: AMG 416; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified June 2013 - Condition: Hypertension
Interventions: Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106); Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106); Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106); Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
Sponsors: Bayer; Bayer
Recruiting - verified May 2013 - Condition: Mantle Cell Lymphoma
Interventions: Drug: Bendamustine; Drug: Rituximab; Drug: Ibrutinib; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Recruiting - verified June 2013 - Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: Simtuzumab (GS-6624); Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified June 2013 - Condition: Erectile Dysfunction
Interventions: Drug: avanafil; Drug: Placebo
Sponsors: VIVUS, Inc.; VIVUS, Inc.
Recruiting - verified May 2013 - Condition: Type 2 Diabetes
Interventions: Drug: lixisenatide (AVE0010); Drug: insulin glulisine (HMR1964)
Sponsors: Sanofi; Sanofi
Recruiting - verified June 2013 - Condition: Dyslipidemia
Interventions: Device: AMG 145; Device: Placebo; Drug: Atorvastatin
Sponsors: Amgen; Amgen
Recruiting - verified June 2013 - Condition: Hyperlipidemia
Interventions: Drug: AMG 145; Other: Ezetimibe; Other: Placebo (administered subcutaneously); Other: Placebo (administered orally); Drug: Statin therapy
Sponsors: Amgen; Amgen
Recruiting - verified June 2013 - Condition: Clinical Safety of the ProMRI Pacemaker System When Used Under Specific MRI Conditions.
Interventions: Device: Patients with a ProMRI Pacemaker System; Other: Magnetic Resonance Imaging (MRI) scan
Sponsors: Biotronik, Inc.; Biotronik, Inc.
Recruiting - verified May 2013 - Conditions: Low Back Pain; Osteoarthritis; Neuropathic Pain
Intervention: Drug: EN3409
Sponsors: Endo Pharmaceuticals; Endo Pharmaceuticals; BioDelivery Science International, Inc. (BDSI)
Recruiting - verified February 2013 - Condition: Postherpetic Neuralgia
Interventions: Drug: Z160; Drug: Placebo
Sponsors: Zalicus; Zalicus
Recruiting - verified June 2013 - Conditions: Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS)
Intervention: Drug: Treosulfan
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program; Resource for Clinical Investigation in Blood and Marrow Transplantation (RCI BMT); Pediatric Blood and Marrow Transplant Consortium; St. Baldrick's Foundation; medac GmbH
Not yet recruiting - verified May 2013 - Condition: Heart Failure
Intervention: Device: Device: Attain Performa Pacing Lead (along with a standard CRT-D system)
Sponsors: Medtronic Cardiac Rhythm Disease Management; Medtronic Cardiac Rhythm Disease Management
Recruiting - verified May 2013 - Condition: Alzheimer's Disease
Interventions: Drug: AC-1204; Drug: Placebo
Sponsors: Accera, Inc.; Accera, Inc.
Recruiting - verified June 2013 - Condition: Alzheimer's Disease
Interventions: Drug: MK-8931; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Conditions: Vaso-occlusive Crisis; Sickle Cell Disease
Interventions: Drug: ANX-188; Drug: Saline
Sponsors: Mast Therapeutics, Inc.; Mast Therapeutics, Inc.
Recruiting - verified June 2013 - Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified June 2013 - Condition: Hemophilia A
Interventions: Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method; Biological: PEGylated Recombinant Factor VIII; Biological: PEGylated Recombinant Factor VIII; Biological: PEGylated Recombinant Factor VIII
Sponsors: Baxter Healthcare Corporation; Baxter Healthcare Corporation
Recruiting - verified June 2013 - Conditions: Pulmonary Hypertension; Chronic Obstructive Pulmonary Disease
Interventions: Drug: Inhaled nitric oxide; Other: Placebo
Sponsors: INO Therapeutics; INO Therapeutics
Recruiting - verified May 2013 - Condition: Type 2 Diabetes in Obese Subjects
Interventions: Device: EndoBarrier; Procedure: Sham Procedure
Sponsors: GI Dynamics; GI Dynamics
Recruiting - verified May 2013 - Conditions: Congenital Bleeding Disorder; Haemophilia A
Intervention: Drug: NNC 0129-0000-1003
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified June 2013 - Condition: Pre Diabetic
Interventions: Drug: Placebo; Drug: NM504:
Sponsors: NuMe Health; NuMe Health
Recruiting - verified May 2013 - Condition: Squamous Cell Non-small Cell Lung Cancer
Intervention: Drug: Nivolumab (BMS-936558)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013 - Condition: Binge Eating Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013 - Condition: Heart Failure
Intervention: Device: Barostim Neo system
Sponsors: CVRx, Inc.; CVRx, Inc.
Recruiting - verified June 2013 - Condition: Colorectal Cancer Metastatic
Interventions: Drug: FOLFOX6m; Device: SIR-Spheres microspheres
Sponsors: Sirtex Medical; Sirtex Medical
Recruiting - verified June 2013 - Condition: Cardiovascular Disease, Diabetes Mellitus, Type 2
Interventions: Drug: aleglitazar; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013 - Conditions: Spinal Stenosis; Spondylolisthesis; Degenerative Disc Disease
Intervention:
Sponsors: Baxano Surgical, Inc.; Baxano Surgical, Inc.
Recruiting - verified June 2013 - Condition: Lupus Nephritis
Interventions: Biological: BMS-188667; Drug: Mycophenolate mofetil; Drug: Prednisone; Biological: Placebo matching with BMS-188667
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified June 2013 - Condition: Alzheimer's Disease
Interventions: Drug: PF-05212377 (SAM-760); Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013 - Condition: Diabetic Nephropathy
Interventions: Drug: PF-04634817; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Rheumatoid Arthritis
Interventions: Drug: sarilumab SAR153191 (REGN88); Other: placebo
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified June 2013 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df; Drug: ritonavir + atazanavir + emtricitabine/tenofovir df
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified June 2013 - Condition: Prediabetes
Interventions: Dietary Supplement: Amylose; Dietary Supplement: Amylopectin
Sponsors: Pennington Biomedical Research Center; Pennington Biomedical Research Center
Recruiting - verified May 2013 - Condition: Tuberous Sclerosis Complex-associated Refractory Seizures
Interventions: Drug: RAD001; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Hypercholesterolemia
Interventions: Drug: alirocumab (REGN727/ SAR236553); Drug: Active Comparator 1 (ezetimibe); Drug: Active Comparator 2 (atorvastatin); Other: Placebo 1 (placebo for ezetimibe atorvastatin); Other: Placebo 2 [alirocumab (REGN727/ SAR236553)]
Sponsors: Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Sanofi
Recruiting - verified May 2013 - Condition: Alzheimer's Disease
Intervention: Drug: florbetapir (18F)
Sponsors: Avid Radiopharmaceuticals; Avid Radiopharmaceuticals; Eli Lilly and Company
Recruiting - verified June 2013 - Condition: Neuropathic Pain
Interventions: Drug: pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Tiotropium; Drug: Placebo matching Olodaterol; Drug: Tiotropium; Drug: Olodaterol
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013 - Condition: Ulcerative Colitis
Interventions: Biological: AMG 181; Other: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified June 2013 - Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque PsoriasisConditions: Psoriasis; Psoriatic Arthritis
Interventions: Drug: Apremilast 30 mg; Drug: Etanercept 50 mg; Drug: Placebo tablet; Drug: Placebo injection (saline)
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified June 2013 - Condition: Chronic Anal Fissures
Interventions: Drug: VEN 307; Drug: Placebo
Sponsors: Ventrus Biosciences, Inc; Ventrus Biosciences, Inc
Recruiting - verified June 2013 - Condition: Cardiovascular Diseases
Interventions: Drug: Evacetrapib; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; The Cleveland Clinic
Recruiting - verified June 2013 - Condition: Moderate to Severe Plaque Psoriasis
Interventions: Drug: 210 mg brodalumab; Drug: 140 mg brodalumab; Drug: ustekinumab; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified June 2013 - Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: QVA149; Drug: Long acting b2-agonist; Drug: QVA149; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013 - Condition: Schizophrenia
Interventions: Drug: ABT-126; Drug: ABT-126; Drug: Placebo
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified June 2013 - Condition: Carcinoid Syndrome
Interventions: Drug: Telotristat etiprate tablets (250 mg); Drug: Placebo tablets
Sponsors: Lexicon Pharmaceuticals; Lexicon Pharmaceuticals
Recruiting - verified May 2013 - Condition: Alzheimer Disease
Interventions: Drug: RO4602522; Drug: RO4601522; Drug: placebo; Drug: donepezil; Drug: rivastigmine; Drug: galantamine; Drug: memantine
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013 - Condition: Acute Myocardial Infarction
Intervention: Device: ClearWay™ Rx catheter
Sponsors: Cardiovascular Institute of the South Clinical Research Corporation; Cardiovascular Institute of the South Clinical Research Corporation
Recruiting - verified May 2013 - Condition: Severe Aortic Stenosis
Intervention: Device: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
Sponsors: Medtronic Cardiovascular; Medtronic Cardiovascular
Recruiting - verified May 2013 - Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Biological: GS-6624 75 mg; Biological: GS-6624 125 mg; Biological: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013 - Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Biological: GS-6624 700mg; Biological: GS-6624 200mg; Biological: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013 - Condition: Primary Sclerosing Cholangitis (PSC)
Interventions: Biological: GS-6624; Biological: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013 - Condition: Arthritis, Rheumatoid
Interventions: Drug: BI 695500; Drug: BI 695500; Drug: rituximab; Drug: rituximab; Drug: rituximab
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium bromide; Drug: Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013 - Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: BAY80-6946
Sponsors: Bayer; Bayer
Recruiting - verified May 2013 - Condition: Ulcerative Colitis
Interventions: Drug: SAR339658; Other: Placebo
Sponsors: Sanofi; Sanofi
Recruiting - verified June 2013 - Conditions: Deep Vein Thrombosis; Venous Thrombosis
Interventions: Drug: edoxaban tosylate; Drug: enoxaparin/unfractionated heparin; Drug: warfarin
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified June 2013 - Condition: Binge Eating Disorder
Intervention: Drug: Lisdexamfetamine dimesylate
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified June 2013 - Condition: Lumbosacral Radiculopathy
Interventions: Drug: z160; Drug: Placebo
Sponsors: Zalicus; Zalicus
Recruiting - verified June 2013 - Condition: Fibrosing Colonopathy in Patients With Cystic Fibrosis
Interventions: Biological: CREON; Biological: ZENPEP; Biological: ULTRESA; Biological: PANCREAZE; Biological: other non-sponsor pancreatic enzyme replacement therapy; Other: No pancreatic enzyme replacement therapy
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott); Aptalis Pharma; Cystic Fibrosis Foundation; Janssen Research & Development, LLC
Recruiting - verified May 2013 - Conditions: Genital Warts; Anal Cancer; Anal Intraepithelial Neoplasia
Intervention: Biological: V503 Vaccine
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: afatinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Available - verified June 2013 - Condition: Rheumatoid Arthritis
Intervention: Drug: Secukinumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013 - Conditions: Inflammation; Rheumatoid Arthritis
Interventions: Drug: NNC0109-0012; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified June 2013 - Condition: Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions: Drug: fingolimod; Drug: copaxone
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013 - Condition: Perennial Allergic Rhinitis (PAR)
Intervention: Drug: Beclomethasone Dipropionate (BDP) Nasal Aerosol
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; United BioSource Corporation
Recruiting - verified May 2013 - Condition: Major Depressive Disorder
Interventions: Drug: Placebo; Drug: Ketamine
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified June 2013 - Conditions: Type 2 Diabetes; Chronic Kidney Disease
Interventions: Drug: Dulaglutide; Drug: Insulin glargine; Drug: Insulin lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013 - Condition: Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.
Intervention: Biological: Darbepoetin alfa
Sponsors: Amgen; Amgen
Recruiting - verified June 2013 - Condition: Cytomegalovirus Infections
Intervention: Drug: Maribavir
Sponsors: ViroPharma; ViroPharma
Recruiting - verified June 2013 - Conditions: Type 2 Diabetes; Cardiovascular Disease
Interventions: Drug: TAK-875; Drug: TAK-875 Placebo
Sponsors: Takeda; Takeda
Recruiting - verified June 2013 - Condition: Arthritis, Rheumatoid
Interventions: Drug: Placebo; Drug: Placebo; Drug: Sirukumab; Drug: Sirukumab; Drug: Sirukumab
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified June 2013 - Condition: Arthritis, Rheumatoid
Interventions: Drug: Placebo; Drug: Placebo; Drug: Sirukumab; Drug: Sirukumab; Drug: Sirukumab
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified June 2013 - Conditions: Childhood Central Nervous System Choriocarcinoma; Childhood Central Nervous System Embryonal Tumor; Childhood Central Nervous System Germ Cell Tumor; Childhood Central Nervous System Germinoma; Childhood Central Nervous System Mixed Germ Cell Tumor; Childhood Central Nervous System Teratoma; Childhood Central Nervous System Yolk Sac Tumor; Childhood Pineal Parenchymal Tumor
Interventions: Procedure: therapeutic conventional surgery; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy; Drug: carboplatin; Drug: etoposide; Drug: ifosfamide
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Interventions: Drug: Ibrutinib; Drug: Bendamustine hydrochloride; Drug: Rituximab; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Recruiting - verified June 2013 - Condition: Psoriasis
Interventions: Drug: 80 mg ixekizumab Dosing Regimen; Drug: 50 mg etanercept; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013 - Condition: Systemic Lupus Erythematosus
Interventions: Biological: Belimumab plus Early Vaccination; Biological: Belimumab plus Late Vaccination
Sponsors: GlaxoSmithKline; Human Genome Sciences Inc., a GSK Company; GlaxoSmithKline
Recruiting - verified February 2013 - Condition: Severe Aortic Stenosis
Interventions: Device: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Procedure: Surgical Aortic Valve Replacement (SAVR)
Sponsors: Medtronic Cardiovascular; Medtronic Cardiovascular
Recruiting - verified June 2013 - Conditions: Advanced Renal Cell Carcinoma; Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma
Interventions: Drug: Standard Treatment; Biological: AGS-003
Sponsors: Argos Therapeutics; Argos Therapeutics
Recruiting - verified June 2013 - Conditions: Carcinoid Tumor of the Small Bowel; Neuroendocrine Tumour
Interventions: Drug: Octreotide; Drug: Octreotide; Drug: 177Lu-DOTA0-Tyr3-Octreotate
Sponsors: Advanced Accelerator Applications; Advanced Accelerator Applications; Pierrel Research Europe GmbH
Recruiting - verified June 2013 - Condition: Asthma
Interventions: Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4; Other: Placebo DPI; Drug: Flovent Diskus 250 mcg
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified May 2013 - Condition: Smoking Cessation
Interventions: Drug: placebo; Drug: varenicline tartrate; Drug: bupropion hydrochloride; Drug: Nicotine Replacement Therapy Patch
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Postmenopausal Osteoporosis
Interventions: Drug: AMG 785; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified June 2013 - Condition: Colorectal Cancer Metastatic
Interventions: Drug: AFLIBERCEPT AVE0005; Drug: FOLFIRI
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified June 2013 - Condition: Hemophilia A
Intervention: Biological: BAY94-9027
Sponsors: Bayer; Bayer
Recruiting - verified May 2013 - Condition: Schizophrenia
Intervention: Drug: Lurasidone
Sponsors: Sunovion; Sunovion
Recruiting - verified May 2013 - Condition: Myelodysplastic Syndrome
Interventions: Drug: Oral Azacitidine; Drug: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified June 2013 - Condition: Major Depressive Disorder, Recurrent
Interventions: Drug: MK-6096; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Conditions: Breast Cancer; Colon Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2012 - Conditions: Parkinson's Disease; Primary Parkinsonism; Lewy Body Parkinson's Disease
Intervention: Drug: 18F-AV-133
Sponsors: Avid Radiopharmaceuticals; Avid Radiopharmaceuticals
Recruiting - verified June 2013 - Conditions: Chlamydia Infections; Gonorrhea
Intervention: Device: APTIMA Assays; PANTHER System
Sponsors: Gen-Probe, Incorporated; Gen-Probe, Incorporated
Recruiting - verified June 2013 - Condition: Irritable Bowel Syndrome With Diarrhea
Interventions: Drug: rifaximin; Drug: placebo
Sponsors: Salix Pharmaceuticals; Salix Pharmaceuticals
Recruiting - verified January 2013 - Condition: Colorectal Neoplasms
Intervention: Drug: Regorafenib (BAY73-4506)
Sponsors: Bayer; Bayer
Available - verified June 2013 - Condition: Schizophrenia
Interventions: Drug: PP3M 175 mg eq.; Drug: PP3M 263 mg eq.; Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.; Drug: Placebo (20% Intralipid emulsion)
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified June 2013 - Condition: Severe Aortic Stenosis
Intervention: Device: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
Sponsors: Medtronic Cardiovascular; Medtronic Cardiovascular
Recruiting - verified May 2013 - Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: afatinib; Drug: erlotinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013 - Conditions: Metastatic Castration-resistant Prostate Cancer; Metastatic Breast Cancer
Interventions: Drug: Abiraterone acetate; Drug: Abiraterone acetate
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013 - Condition: Prostatic Neoplasms
Intervention: Drug: Radium-223 dichloride (BAY88-8223)
Sponsors: Bayer; Bayer
Available - verified June 2013 - Condition: Schizophrenia
Interventions: Drug: PP3M 175 mg eq.; Drug: PP3M 263 mg eq.; Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.; Drug: Placebo (20% Intralipid); Drug: PP1M 50 mg eq.; Drug: PP1M 75 mg eq.; Drug: PP1M 100 mg eq.; Drug: PP1M 150 mg eq.
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified June 2013 - Condition: Psoriasis
Intervention: Drug: etanercept
Sponsors: Amgen; Amgen
Recruiting - verified June 2013 - Conditions: Prostate Cancer; Castration Resistant Prostate Cancer; Pain; Prostatic Neoplasms
Interventions: Drug: cabozantinib; Drug: mitoxantrone; Drug: prednisone
Sponsors: Exelixis; Exelixis
Recruiting - verified June 2013 - Conditions: Childhood Hepatocellular Carcinoma; Papillary Thyroid Cancer; Previously Treated Childhood Rhabdomyosarcoma; Recurrent Childhood Liver Cancer; Recurrent Childhood Rhabdomyosarcoma; Recurrent Thyroid Cancer; Recurrent Wilms Tumor and Other Childhood Kidney Tumors
Interventions: Drug: sorafenib tosylate; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified June 2013 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: onartuzumab; Drug: Placebo; Drug: paclitaxel; Drug: cisplatin/carboplatin
Sponsors: Genentech; Genentech
Recruiting - verified May 2013 - Condition: Hemophilia B
Intervention: Biological: rIX-FP
Sponsors: CSL Behring; CSL Behring
Recruiting - verified June 2013 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: RO5490258; Drug: bevacizumab [Avastin]; Drug: pemetrexed; Drug: Placebo; Drug: cisplatin/carboplatin; Drug: paclitaxel
Sponsors: Genentech; Genentech
Recruiting - verified May 2013 - Condition: Epilepsy
Intervention: Drug: Lacosamide
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2013 - Conditions: Atrial Fibrillation; Paroxysmal Atrial Fibrillation; Persistent Atrial Fibrillation
Interventions: Drug: OPC-108459; Drug: Placebo
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified May 2013 - Conditions: Congenital Bleeding Disorder; Haemophilia A
Intervention: Drug: NNC 0129-0000-1003
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified June 2013 - Condition: Asthma
Interventions: Drug: Placebo; Drug: Flovent Diskus; Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; PPD
Recruiting - verified May 2013 - Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component
Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: Temozolomide; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified June 2013 - Condition: HER2 Negative Breast Cancer
Interventions: Biological: NeuVax vaccine; Biological: Leukine (sargramostim, GM-CSF) and water for injection
Sponsors: Galena Biopharma, Inc.; Galena Biopharma, Inc.
Recruiting - verified June 2013 - Condition: Hemophilia A
Intervention: Biological: Recombinant Factor VIII (rFVIII)
Sponsors: CSL Behring; CSL Behring
Recruiting - verified June 2013 - Condition: Colorectal Cancer
Interventions: Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: Placebo; Drug: FOLFIRI
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013 - Conditions: Coronary Artery Disease; Hypertriglyceridemia
Interventions: Drug: LCQ908; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Central Precocious Puberty
Intervention: Drug: Triptorelin 22.5 mg
Sponsors: Debiopharm S.A.; Debiopharm S.A.
Recruiting - verified May 2013 - Conditions: Stroke; Atrial Fibrillation
Intervention:
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013 - Condition: Painful Diabetic Peripheral Neuropathy
Interventions: Drug: pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Smoking Cessation
Interventions: Drug: Placebo; Drug: varenicline tartrate; Drug: bupropion hydrochloride; Drug: Nicotine Replacement Therapy Patch
Sponsors: Pfizer; Pfizer; GlaxoSmithKline
Recruiting - verified May 2013 - Conditions: Pulmonary Arterial Hypertension; Pulmonary Hypertension
Interventions: Drug: Nitric Oxide; Other: Placebo; Drug: Nitric Oxide
Sponsors: INO Therapeutics; INO Therapeutics
Recruiting - verified May 2013 - Condition: Depression Disorder, Major
Interventions: Drug: RO4917523; Drug: RO4917523; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013 - Condition: Major Depressive Disorder
Interventions: Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate ); Drug: Antidepressant + Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified June 2013 - Condition: Low Back Pain
Interventions: Drug: Oxycodone/Naloxone controlled-release; Drug: Oxycodone HCl controlled-release; Drug: Placebo
Sponsors: Purdue Pharma LP; Purdue Pharma LP
Recruiting - verified June 2013 - Condition: Endometrial Neoplasms
Interventions: Drug: PF-05212384; Drug: PF-05212384; Drug: PF-05212384
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013 - Conditions: Ejaculatory Dysfunction; Hypogonadism
Interventions: Drug: Testosterone Solution 2%; Drug: Placebo Solution
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013 - Condition: Infections, Pediatrics
Interventions: Drug: Ceftaroline fosamil; Drug: Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam; Drug: Cephalexin or Clindamycin or Linezolid
Sponsors: Cerexa, Inc.; Cerexa, Inc.; AstraZeneca
Recruiting - verified June 2013 - Condition: Depression, Bipolar
Interventions: Drug: Placebo; Drug: Cariprazine; Drug: Cariprazine; Drug: Cariprazine
Sponsors: Forest Laboratories; Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified May 2013 - Condition: Bipolar I Disorder
Interventions: Drug: asenapine; Drug: asenapine
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Conditions: Cardiovascular Disease; Diabetes Mellitus, Type 2
Interventions: Drug: Dulaglutide; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013 - Condition: Chronic Graft Versus Host Disease
Interventions: Drug: ECP(Methoxsalen)+Corticosteroids+Cyclosporine or Tacrolimus; Drug: Corticosteroids/Cyclosporine/Tacrolimus
Sponsors: Therakos; Therakos; Parexel
Recruiting - verified June 2013 - Condition: Major Depressive Disorder
Interventions: Drug: Desvenlafaxine Succinate Sustained-Release; Drug: Desvenlafaxine Succinate Sustained-Release; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Major Depressive Disorder
Intervention: Drug: DVS SR
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Major Depressive Disorder
Interventions: Drug: desvenlafaxine succinate sustained release; Drug: fluoxetine; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Major Depressive Disorder
Intervention: Drug: DVS SR
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Conditions: Crohn's Disease; Colitis; IBD; Inflammatory Bowel Disease
Interventions: Drug: Placebo; Drug: Ustekinumab; Drug: Ustekinumab; Drug: Ustekinumab; Drug: Ustekinumab
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified June 2013 - Conditions: Crohn's Disease; Inflammatory Bowel Disease; IBD; Colitis
Interventions: Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo; Drug: Group 2 ustekinumab 130 mg
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified June 2013 - Conditions: Pain; Advanced Cancer
Interventions: Drug: Sativex®; Drug: Placebo (GA-0034)
Sponsors: GW Pharmaceuticals Ltd.; GW Pharmaceuticals Ltd.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified August 2011 - Condition: Healthy
Interventions: Biological: rLP2086; Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Standard of care treatment
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013 - Condition: Rheumatoid Arthritis
Interventions: Drug: Secukinumab (75 mg); Drug: Secukinumab (150 mg); Drug: Placebo; Drug: Abatacept
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013 - Conditions: SCID; ADA-SCID; XSCID; Leaky SCID; Omenn Syndrome; Reticular Dysgenesis
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Office of Rare Diseases (ORD)
Recruiting - verified May 2013 - Condition: Head and Neck Neoplasms
Interventions: Drug: Placebo; Drug: Afatinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013 - Condition: HIV-1
Interventions: Drug: Maraviroc; Drug: Emtricitabine/tenofovir
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified June 2013 - Condition: Advanced Liposarcoma or Leiomyosarcoma
Interventions: Drug: Trabectedin; Drug: Dacarbazine
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharma Mar, S.A.U.
Recruiting - verified June 2013 - Condition: Coronary Artery Disease
Intervention: Drug: Flurpiridaz F18
Sponsors: Lantheus Medical Imaging; Lantheus Medical Imaging
Recruiting - verified February 2013 - Condition: Hepatitis C
Interventions: Drug: BI 201335; Drug: PegIFN/RBV
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013 - Condition: Hepatitis C
Intervention: Drug: TMC435
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified May 2013 - Condition: Prostate Cancer Metastatic
Interventions: Biological: PROSTVAC-V; Biological: PROSTVAC-F; Drug: GM-CSF; Other: GM-CSF Placebo; Biological: Placebo
Sponsors: BN ImmunoTherapeutics; BN ImmunoTherapeutics
Recruiting - verified February 2013 - Condition: Smoking Cessation
Interventions: Drug: Varenicline 1mg BID; Drug: Varenicline 0.5mg BID; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Symptomatic Severe Aortic Stenosis
Interventions: Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: AVR with a surgical heart valve; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: AVR with a surgical heart valve; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis
Sponsors: Edwards Lifesciences; Edwards Lifesciences
Recruiting - verified May 2013 - Conditions: Prostate Cancer; Prostatic Neoplasm
Intervention: Drug: abiraterone acetate in combination with prednisone
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified May 2013 - Condition: Crohn's Disease
Intervention: Drug: GSK1605786A
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified June 2013 - Condition: Crohn's Disease
Interventions: Drug: GSK1605786A; Drug: Placebo; Drug: GSK1605786A
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Conditions: Fungal Infection; Leukemia; Neutropenia
Interventions: Drug: caspofungin acetate; Drug: fluconazole
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Haemophilia A
Intervention: Biological: Recombinant Factor VIII (BAY81-8973)
Sponsors: Bayer; Bayer
Recruiting - verified May 2013 - Condition: HIV Infections
Interventions: Drug: GSK1349572 tablet formulation; Drug: GSK1349572 oral pediatric granules taken as suspension or granules
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2013 - Condition: Infections
Interventions: Drug: E-101 Solution 300 GU/ml; Drug: Saline solution
Sponsors: Excited States, LLC; Excited States, LLC; Beardsworth Consulting Group, Inc.; Veristat, Inc.; Biotec Services International Ltd; Eurofins Medinet; CBR International Corp.
Recruiting - verified June 2013 - Condition: Systemic Lupus Erythematosus
Interventions: Drug: Placebo; Drug: Epratuzumab; Drug: Epratuzumab
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2013 - Condition: Systemic Lupus Erythematosus
Interventions: Drug: Epratuzumab; Drug: Epratuzumab; Drug: Placebo
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2013 - Conditions: Colorectal Neoplasms; Digestive System Diseases; Colonic Diseases; Colorectal Cancer
Intervention:
Sponsors: Exact Sciences Corporation; Exact Sciences Corporation
Recruiting - verified May 2013 - Condition: Critical Limb Ischemia
Interventions: Device: BMAC injection; Device: Placebo injection
Sponsors: Harvest Technologies; Harvest Technologies
Recruiting - verified May 2013 - Condition: Bipolar Disorder, Pediatric
Interventions: Drug: asenapine; Drug: Placebo to match asenapine; Drug: Rescue medication
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Conditions: Adult Supratentorial Primitive Neuroectodermal Tumor (PNET); Childhood Supratentorial Primitive Neuroectodermal Tumor; Ewing Sarcoma of Bone; Extraosseous Ewing Sarcoma; Extraosseous Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Peripheral Primitive Neuroectodermal Tumor of the Kidney; Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions: Drug: vincristine sulfate; Drug: doxorubicin hydrochloride; Drug: cyclophosphamide; Drug: ifosfamide; Drug: etoposide; Drug: topotecan hydrochloride; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Condition: Polycystic Kidney, Autosomal Dominant
Interventions: Drug: Bosutinib; Drug: Bosutinib; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013 - Condition: Head and Neck Cancer
Interventions: Drug: cisplatin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Conditions: Prostate Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male
Intervention: Drug: Abiraterone Acetate
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified May 2013 - Conditions: Systemic Lupus Erythematosus; Connective Tissue Disease; Autoimmune Disease
Interventions: Drug: LY2127399; Drug: Placebo every 2 weeks; Drug: Placebo every 4 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013 - Condition: Lymphoma, Follicular
Interventions: Biological: Ofatumumab; Biological: Rituximab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Diabetic Nephropathies
Interventions: Drug: PF-00489791; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013 - Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Conditions: SCID; Leaky SCID; Omenn Syndrome; Reticular Dysgenesis; ADA Deficiency; XSCID
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Office of Rare Diseases (ORD)
Recruiting - verified May 2013 - Conditions: Light Chain Deposition Disease; Smoldering Multiple Myeloma
Interventions: Other: clinical observation; Drug: lenalidomide; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Hypertension, Pulmonary
Interventions: Drug: ambrisentan; Drug: tadalafil
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Gilead Sciences
Recruiting - verified May 2013 - Conditions: Childhood Hepatoblastoma; Previously Treated Childhood Rhabdomyosarcoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Malignant Germ Cell Tumor; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Neuroblastoma; Recurrent Osteosarcoma; Recurrent Wilms Tumor and Other Childhood Kidney Tumors
Interventions: Drug: alisertib; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Condition: Non Squamous Lung Cancer
Interventions: Drug: treatment; Drug: treatment
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013 - Condition: Acute Coronary Syndrome
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo
Sponsors: Sanofi; Sanofi
Recruiting - verified June 2013 - Condition: Smallpox
Interventions: Biological: IMVAMUNE; Biological: IMVAMUNE; Biological: IMVAMUNE; Other: Placebo
Sponsors: Bavarian Nordic; Bavarian Nordic
Recruiting - verified May 2013 - Conditions: Diabetic Kidney Disease; Diabetic Nephropathy; Diabetic Glomerulosclerosis
Interventions: Drug: LY2382770; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013 - Conditions: Abscess, Intra-Abdominal; Abdominal Abscess; Abdomen, Acute; Abdominal Pain; Appendicitis; Rupture; Infection; Intestinal Perforation; Peritonitis; Ileus
Interventions: Drug: doripenem; Drug: meropenem placebo; Drug: meropenem; Drug: doripenem placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified June 2013 - Condition: Complicated Urinary Tract Infections or Pyelonephritis
Interventions: Drug: doripenem; Drug: doripenem placebo; Drug: cefepime; Drug: cefepime placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013 - Condition: Includes: Hereditary Angioedema
Intervention: Biological: Berinert® (C1 Esterase Inhibitor)
Sponsors: CSL Behring; CSL Behring; Chiltern International Inc.
Recruiting - verified May 2013 - Condition: Cardiovascular Disease
Interventions: Drug: Febuxostat; Drug: Allopurinol
Sponsors: Takeda; Takeda
Recruiting - verified June 2013 - Conditions: brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer
Interventions: Dietary Supplement: cholecalciferol; Other: placebo
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Childhood Infratentorial Ependymoma; Childhood Supratentorial Ependymoma; Newly Diagnosed Childhood Ependymoma
Interventions: Drug: liposomal vincristine sulfate; Other: clinical observation; Radiation: 3-dimensional conformal radiation therapy; Drug: carboplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: cisplatin; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Condition: Pancreatic Cancer
Interventions: Biological: HyperAcute-Pancreas Immunotherapy; Drug: Gemcitabine; Radiation: 5FU Chemoradiation
Sponsors: NewLink Genetics Corporation; NewLink Genetics Corporation
Recruiting - verified June 2013 - Condition: Intraabdominal Infections
Interventions: Drug: Moxifloxacin (Avelox, BAY12-8039); Drug: Ertapenem, Amoxicillin/clavulanate
Sponsors: Bayer; Bayer
Recruiting - verified May 2013 - Condition: HIV Infections
Intervention:
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2013 - Condition: Foot Ulcer, Diabetic
Interventions: Device: Integra® Dermal Regeneration Template; Other: Conventional Wound Therapy
Sponsors: Integra LifeSciences Corporation; Integra LifeSciences Corporation
Recruiting - verified June 2013 - Condition: Infections
Intervention: Drug: Moxifloxacin (Avelox, BAY12-8039)
Sponsors: Bayer; Bayer
Recruiting - verified June 2013 - Condition: Leukaemia, Lymphocytic, Chronic
Interventions: Biological: Ofatumumab; Other: Observation
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified June 2013 - Condition: Stress Disorders, Post-Traumatic
Interventions: Behavioral: Structured Approach Therapy; Behavioral: PTSD Family Education
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified June 2013 - Conditions: Breast Cancer; Cardiac Toxicity
Interventions: Drug: Coreg CR®; Drug: lisinopril; Other: placebo
Sponsors: University of South Florida; University of South Florida; National Cancer Institute (NCI)
Recruiting - verified January 2013 - Condition: Refractory Cutaneous T-cell Lymphoma
Interventions: Drug: bexarotene; Drug: bexarotene
Sponsors: Valeant Pharmaceuticals International, Inc.; Valeant Pharmaceuticals International, Inc.
Recruiting - verified June 2013 - Conditions: Cardiac Surgery; Erythrocyte Transfusion
Interventions: Biological: Red blood cell units stored <= 10 days; Biological: Red blood cell units stored >= 21 days
Sponsors: New England Research Institutes; New England Research Institutes; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2013 - Conditions: Childhood Hepatoblastoma; Stage I Childhood Liver Cancer; Stage II Childhood Liver Cancer; Stage III Childhood Liver Cancer; Stage IV Childhood Liver Cancer
Interventions: Procedure: therapeutic conventional surgery; Drug: cisplatin; Drug: fluorouracil; Drug: vincristine sulfate; Drug: doxorubicin hydrochloride; Drug: irinotecan hydrochloride; Procedure: liver transplantation; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Condition: Lung Cancer
Interventions: Biological: panitumumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Condition: Head and Neck Cancer
Interventions: Biological: cetuximab; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Condition: HIV Infections
Intervention: Drug: Highly active antiretroviral therapy (HAART)
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2013 - Conditions: Pain, Burning; Pain, Crushing; Pain, Migratory; Pain, Radiating; Pain, Splitting
Interventions: Drug: JNJ-42160443; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013 - Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer
Interventions: Biological: Denosumab; Biological: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified June 2013 - Conditions: Adult Rhabdomyosarcoma; Childhood Desmoplastic Small Round Cell Tumor; Chordoma; Desmoid Tumor; Metastatic Childhood Soft Tissue Sarcoma; Nonmetastatic Childhood Soft Tissue Sarcoma; Previously Treated Childhood Rhabdomyosarcoma; Previously Untreated Childhood Rhabdomyosarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Stage I Adult Soft Tissue Sarcoma; Stage II Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma
Interventions: Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Conditions: Leukemia; Lymphoma
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: bortezomib; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Condition: HIV Infection
Intervention: Drug: All licensed antiretroviral medications
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); Copenhagen HIV Programme (CHIP) -- Copenhagen, Denmark; Medical Research Council (MRC) Clinical Trials Unit -- London, United Kingdom; The Kirby Institute for Infection and Immunity in Society; The Institute for Clinical Research at the Veterans Affairs Medical Center -- Washington, D.C., USA; French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS); German Federal Ministry of Education and Research; NEAT - European AIDS Treatment Network; National Health and Medical Research Council, Australia; National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI); National Institute of Mental Health (NIMH); National Institute of Neurological Disorders and Stroke (NINDS); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Abbott; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Merck; Tibotec Pharmaceutical Limited
Recruiting - verified June 2013 - Condition: Human Immuno Deficiency (HIV) Infections
Interventions: Drug: TMC278; Drug: Zidovudine; Drug: Abacavir; Drug: Tenofovir disoproxil fumarate; Drug: Lamivudine; Drug: Emtricitabine
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified June 2013 - Conditions: Adult Acute Lymphoblastic Leukemia in Remission; B-cell Adult Acute Lymphoblastic Leukemia; L1 Adult Acute Lymphoblastic Leukemia; L2 Adult Acute Lymphoblastic Leukemia; Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; T-cell Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: vincristine sulfate; Drug: dexamethasone; Drug: dasatinib; Drug: cytarabine; Drug: methotrexate; Biological: filgrastim; Drug: methylprednisolone; Drug: leucovorin calcium; Drug: prednisone; Radiation: total-body irradiation; Drug: etoposide; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Drug: sirolimus; Drug: tacrolimus; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified June 2013 - Conditions: Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Other: questionnaire administration; Procedure: cognitive assessment; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Condition: ST-Elevation Myocardial Infarction
Intervention: Device: Life Recovery Systems ThermoSuit
Sponsors: Life Recovery Systems; Life Recovery Systems
Not yet recruiting - verified June 2013 - Conditions: Candidemia; Candidiasis
Interventions: Drug: anidulafungin; Drug: fluconazole
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Lung Cancer
Intervention: Radiation: stereotactic body radiation therapy (SBRT)
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Condition: Sickle Cell Disease
Intervention: Biological: Hematopoietic Stem Cell Transplantation
Sponsors: Medical College of Wisconsin; Medical College of Wisconsin; National Heart, Lung, and Blood Institute (NHLBI); Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute (NCI); National Marrow Donor Program; Sickle Cell Disease Clinical Research Network
Recruiting - verified May 2013 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Acute Myeloid Leukemia/Transient Myeloproliferative Disorder; Acute Undifferentiated Leukemia; Angioimmunoblastic T-cell Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Burkitt Lymphoma; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Grade III Lymphomatoid Granulomatosis; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Cutaneous B-cell Non-Hodgkin Lymphoma; Essential Thrombocythemia; Extramedullary Plasmacytoma; Intraocular Lymphoma; Isolated Plasmacytoma of Bone; Juvenile Myelomonocytic Leukemia; Long-term Effects Secondary to Cancer Therapy in Children; Mast Cell Leukemia; Meningeal Chronic Myelogenous Leukemia; Monoclonal Gammopathy of Undetermined Significance; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Polycythemia Vera; Post-transplant Lymphoproliferative Disorder; Primary Central Nervous System Hodgkin Lymphoma; Primary Central Nervous System Non-Hodgkin Lymphoma; Primary Myelofibrosis; Primary Systemic Amyloidosis; Progressive Hairy Cell Leukemia, Initial Treatment; Prolymphocytic Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Stage 0 Chronic Lymphocytic Leukemia; Stage I Childhood Anaplastic Large Cell Lymphoma; Stage I Childhood Hodgkin Lymphoma; Stage I Childhood Large Cell Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Childhood Small Noncleaved Cell Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Multiple Myeloma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage II Childhood Anaplastic Large Cell Lymphoma; Stage II Childhood Hodgkin Lymphoma; Stage II Childhood Large Cell Lymphoma; Stage II Childhood Lymphoblastic Lymphoma; Stage II Childhood Small Noncleaved Cell Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Childhood Anaplastic Large Cell Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Childhood Small Noncleaved Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage IV Childhood Anaplastic Large Cell Lymphoma; Stage IV Childhood Hodgkin Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Childhood Small Noncleaved Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; T-cell Large Granular Lymphocyte Leukemia; Unspecified Childhood Solid Tumor, Protocol Specific; Untreated Childhood Acute Lymphoblastic Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies; Untreated Hairy Cell Leukemia; Waldenström Macroglobulinemia
Interventions: Other: survey administration; Procedure: assessment of therapy complications; Procedure: long-term screening; Procedure: study of high risk factors
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Condition: Human Immunodeficiency Virus
Interventions: Drug: Maraviroc along with an optimized background antiretroviral drug regimen; Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2013 - Conditions: Diabetic Type 1 With Obstructive Pulmonary Disease; Diabetic Type 2 With Obstructive Pulmonary Disease; Asthma; COPD; Type 1 Diabetes; Type 2 Diabetes; Indeterminate Obstructive Lung Disease
Interventions: Drug: Technosphere Insulin; Drug: Usual Care
Sponsors: Mannkind Corporation; Mannkind Corporation
Recruiting - verified May 2013 - Condition: Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy; Drug: cisplatin; Drug: etoposide
Sponsors: Alliance for Clinical Oncology Trials; Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group; Eastern Cooperative Oncology Group; North Central Cancer Treatment Group; Southwestern Oncology Group (SWOG)
Recruiting - verified June 2013 - Conditions: Aspergillosis; Invasive Fungal Infections
Intervention: Drug: isavuconazole
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Basilea Pharmaceutica
Recruiting - verified June 2013 - Conditions: Crohn's Disease; Ulcerative Colitis; Indeterminate Colitis; Inflammatory Bowel Diseases
Interventions: Biological: Anti TNF therapy including infliximab; Drug: No Biologics
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified June 2013 - Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: flutamide; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified June 2013 - Condition: Influenza
Interventions: Drug: oseltamivir; Drug: oseltamivir; Other: Alternative Control
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013 - Condition: Influenza
Interventions: Biological: 13 valent pneumococcal conjugate vaccine; Biological: 13 valent pneumococcal conjugate vaccine
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013 - Conditions: Psoriasis; Arthritis, Psoriatic
Interventions: Biological: ustekinumab; Biological: Biological therapies other than infliximab and ustekinumab; Drug: conventional systemic agents; Biological: infliximab
Sponsors: Centocor Ortho Biotech Services, L.L.C.; Centocor Ortho Biotech Services, L.L.C.
Recruiting - verified June 2013 - Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013 - Conditions: Untreated Childhood Medulloblastoma; Untreated Childhood Pineoblastoma; Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions: Drug: carboplatin; Drug: cyclophosphamide; Biological: filgrastim; Drug: cisplatin; Drug: isotretinoin; Drug: vincristine sulfate; Radiation: radiation therapy; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Condition: Kidney Neoplasms
Interventions: Drug: Sunitinib malate; Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013 - Condition: Optic Nerve Diseases
Intervention: Drug: Zyvox - linezolid
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Conditions: Arthritis, Rheumatoid; Osteoarthritis
Interventions: Drug: celecoxib; Drug: Ibuprofen; Drug: Naproxen
Sponsors: Pfizer; Pfizer; The Cleveland Clinic
Recruiting - verified June 2013 - Conditions: Breast Cancer; Neoplasm Metastasis
Interventions: Other: Standard supportive care (packed RBC transfusion); Drug: epoetin alfa + packed RBC transfusion
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013 - Condition: Kidney Cancer
Interventions: Biological: dactinomycin; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: therapeutic conventional surgery; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Conditions: Untreated Childhood Medulloblastoma; Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions: Drug: etoposide; Drug: cyclophosphamide; Drug: cisplatin; Biological: filgrastim; Drug: carboplatin; Drug: thiotepa; Drug: methotrexate; Drug: leucovorin calcium; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Condition: Sarcoma
Intervention: Drug: Trabectedin
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013 - Condition: HIV Infection
Intervention: Drug: Efavirenz
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Available - verified May 2013 - Conditions: Brain Tumor; Central Nervous System Tumor
Interventions: Drug: cisplatin; Drug: cyclophosphamide; Drug: lomustine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Conditions: Cancer Survivor; Cardiovascular Complications; Hematopoietic/Lymphoid Cancer; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Other: questionnaire administration; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013 - Condition: HIV Infections
Intervention: Drug: Tipranavir
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Available - verified June 2013 - Condition: HIV Infections
Interventions: Drug: Current ARV medications; Drug: Current TB medications; Drug: Current hormonal contraceptive medications
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2013 - Conditions: HIV Infections; Pregnancy Complications, Infectious
Intervention: Behavioral: Adherence assessment
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified June 2013
 |
Find Paid Research Studies in Louisiana |
Clinical Trial Locations 